← Back to Home

What Happens When an Alzheimer’s Blood Test Falls in the Gray Zone? A Two-Stage Strategy Helps Clarify Amyloid Status

By testing p-Tau217 first, then adding other blood markers, age, and genetic risk for those with inconclusive results, the GRAD model could reduce unresolved diagnostic results. However, prospective studies are still needed to confirm whether it can actually reduce the burden of imaging.

By SURL BioNews

Blood testing makes it easier to access testing for Alzheimer’s-related pathology, but it may not immediately provide a clear answer. When values fall within a difficult-to-interpret “gray zone,” people may still need an amyloid positron emission tomography (PET) scan to clarify whether related deposits are present in the brain. A new study explores adding a selective interpretive step between blood testing and imaging.

The GRAD model, jointly developed by teams at Boston University and the University of Connecticut, uses a two-stage strategy: it first assesses the blood marker phosphorylated tau, p-Tau217; only when results are inconclusive does it incorporate other blood biomarkers, age, and genetic risk information. Although the starting point is a tau-related marker, the study’s central aim remains to identify amyloid status in the brain.

The study was published in Annals of Clinical and Translational Neurology. The team first developed the model using data from 145 people with memory or thinking difficulties in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). All participants had blood biomarker and amyloid PET data, allowing the researchers to use imaging results as a reference to evaluate the blood-testing workflow’s ability to distinguish amyloid status.

The team then evaluated the same strategy in a separate group of 1,644 cognitively unimpaired participants in the A4/LEARN studies. Of these, 630 had p-Tau217 results in the gray zone. After incorporating second-stage information, the model improved identification of amyloid status and reduced the proportion deemed to still require PET scans under the study protocol. This independent evaluation covered a clinical population different from the one used to develop the model, but it does not establish that routine clinical care would achieve the same benefits.

The potential value of this workflow lies in concentrating additional testing on people whose results are hardest to interpret. According to the research team, if future validation is successful, GRAD could help physicians arrange confirmatory testing. It could also be used in Alzheimer’s prevention and treatment trials to screen large pools of potential participants for people who may have amyloid deposits in the brain.

The current limits remain clear: the study shows improved interpretation of existing data and a potential reduction in the need for imaging, rather than proof that the approach reduces testing in actual clinical workflows. The team emphasized that GRAD still requires prospective testing before it can be considered for routine care and cannot currently replace confirmatory imaging. Reducing the gray zone is a step forward; maintaining reliable interpretation in real-world clinical care is the next test.

References

  1. Boston University School of Medicine / Medical Xpress
  2. Boston University Chobanian & Avedisian School of Medicine